Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Targeted Tumor Vaccines

Group Leader


Dr. med. Angel Cid-Arregui

+49 (0) 6221 423714

Adaptive and innate immunity research for cervical cancer immunotherapy

Our research is aimed at understanding adaptive and innate immune responses to HPV-associated malignancies and developing vaccine and tumor-targeting strategies useful to treat cancer. To this end, we have focused on the design of vaccines based on chimeric fusion proteins, such as those carrying the hepatitis B surface antigen (HBsAg-S) and parts of the HPV16 E6 and E7 proteins. We also have designed and constructed chimeric proteins carrying tumor neoantigens derived from mutated Ras and p53 linked to cytokines, which are proving useful for the identification of T cells that recognize HLA-A2-restricted neo-epitopes. The isolated cells are used for single-cell sequencing of their TCRs. The identified TCRs are then tested for functionality in vitro and in vivo.

In addition, we are interested in understanding the pathophysiological significance of changes in circulating levels of cytokines during progression from cervical intraepithelial neoplasia (CIN) to cervical cancer (CC). A cohort of patients diagnosed with different grades of CIN and CC patients, as well as a healthy control group are currently being recruited and analyzed. With this study we hope to find diagnostic and prognostic markers for CC. Furthermore, we develop targeted drug delivery systems to facilitate the administration of chemotherapy drugs primarily to tumor cells, thereby minimizing side effects. Currently, we are approaching the targeting of nanoparticles to tumor cells and antigen presenting cells using various types of binding molecules.

to top
powered by webEdition CMS